Inhibikase Therapeutics Inc Cash Flow Conversion Efficiency
Inhibikase Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.59 Million) by net assets ($72.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Inhibikase Therapeutics Inc (2016–2024)
Cash flow conversion efficiency of Inhibikase Therapeutics Inc from 2016 to 2024. This chart illustrates how Inhibikase Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IKT stock price and chart for real-time trading data and today's change.
Inhibikase Therapeutics Inc Cash Flow Conversion Ratio Explained
Inhibikase Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Inhibikase Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibikase Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Inhibikase Therapeutics Inc (IKT) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MSM Malaysia Holdings Bhd
KLSE:5202
|
0.058x |
|
Affluent Medical SAS
PA:AFME
|
-0.319x |
|
GoldMoney Inc
TO:XAU
|
0.050x |
|
Solteam Electronics Co Ltd
TWO:3484
|
0.040x |
|
TCM Group
CO:TCM
|
0.087x |
|
Poh Kong Holdings Bhd
KLSE:5080
|
-0.004x |
|
OCK Group Bhd
KLSE:0172
|
-0.030x |
|
I Controls Inc
KO:039570
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Inhibikase Therapeutics Inc from 2016 to 2024. Review free cash flow generation of Inhibikase Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $94.87 Million | $-19.15 Million | -0.202x | +87.75% |
| 2023-12-31 | $10.98 Million | $-18.09 Million | -1.647x | -99.72% |
| 2022-12-31 | $21.04 Million | $-17.35 Million | -0.825x | -121.63% |
| 2021-12-31 | $38.42 Million | $-14.30 Million | -0.372x | -222.43% |
| 2020-12-31 | $9.78 Million | $-1.13 Million | -0.115x | -253.20% |
| 2019-12-31 | $-4.49 Million | $-338.29K | 0.075x | +108.20% |
| 2018-12-31 | $-777.97K | $714.99K | -0.919x | -1147.82% |
| 2017-12-31 | $-1.44 Million | $-126.39K | 0.088x | +300.90% |
| 2016-12-31 | $-1.35 Million | $-29.57K | 0.022x | -- |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more